Basking Biosciences

Executive Summary

Basking Biosciences is a pre-clinical biotech company developing a novel, reversible RNA-based therapy targeting von Willebrand Factor (vWF) for acute thrombotic conditions, with an initial focus on acute ischemic stroke. Founded in 2019 and based in Columbus, Ohio, the company aims to address the limitations of current thrombolytics by offering rapid onset of action and a direct-acting reversal agent, potentially enabling safer clot dissolution. Its lead program leverages a proprietary RNA aptamer platform to inhibit vWF, a key mediator of platelet aggregation and thrombosis. The therapy is designed to be rapidly reversible with an antidote, providing a unique safety advantage over existing treatments. Basking's approach has the potential to expand the therapeutic window for stroke patients and reduce bleeding complications. The company is currently in the pre-clinical stage, with plans to advance its lead candidate into IND-enabling studies. While the science is compelling, the early stage of development and lack of publicly disclosed funding or partnerships present risks. Conviction Score: 65.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for Lead Program70% success
• Q2 2026Series A Financing80% success
• H2 2027Initial Phase 1 Data Readout50% success